

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
(Modified) PATENT AND TRADEMARK OFFICEINFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

(37 CFR 1.98 (b))

ATTY. DOCKET NO.

7050.US.02

SERIAL NO.

10/802,829

APPLICANT(S)

Kempf et al.

FILING DATE

March 18, 2004

GROUP

1614

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	PATENT NUMBER	ISSUE DATE	INVENTOR	CLASS	SUB CLASS	FILING DATE
<i>[Signature]</i>	A1 6,037,157	03/14/2000	Kempf et al. Norbeck			06/26/1996

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUB CLASS	TRANS- LATION YES NO

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

<i>[Signature]</i>	C1	Agarwala et al., "Steady state pharmacokinetic (PK) interaction study of Atazanavir (ATV) with Ritonavir (RTV) in healthy subjects," Poster presented at the 42 nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, September 27-30 th , 2002
	C2	O'Mara et al., "Relationship between uridine diphosphate-glucuronosyl transferase (UDP-GT) 1A1 Genotype and total bilirubin elevations in healthy subjects receiving BMS-232632 and saquinavir," Poster presented at the 40 th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, Canada, September 17-20, 2000
	C3	Zucker et al., "Mechanism of indinavir-induced hyperbilirubinemia," PNAS 98(22):12671-12676 (2001)
	C4	Kitter, Joseph K., "Expression and inducibility of the human bilirubin UDP-glucuronosyltransferase UGT1A1 in liver and cultured primary hepatocytes: Evidence for both genetic and environmental influences", Hepatology, Vol. 30, No. 2, Aug. 1999 (1999-08), pp 476-484
	C5	Sugalan, Junko, et al., "The Phenobarbital response enhancer module in the human bilirubin UDP-glucuronosyltransferase UGT1A1 gene and regulation by the nuclear HEPATOLOGY", Vol. 33, No. 5, May 2001-05, pp 1232-1238
	C6	Baede, P., et al., "Drug interactions with TMC125, a potent next generation NNRTI". ABSTRACTS OF THE INTERSCIENCE CONFERENCE ON ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Vol. 42, 2002, page 27 & AMERICAN SOCIETY FOR MICROBIOLOGY (ASM) Annual Meeting on Infectious Disease; San Diego, CA, USA; Sept. 27-30, 2002 abstract
	C7	Penzak, Scott, et al., "Influence of ritonavir on olanzapine pharmacokinetics in healthy volunteers", Journal of Clinical Psychopharmacology, Vol. 22, No. 4, August 2002, pp 366-370
<i>[Signature]</i>	C8	Ouellet Daniele, et al., "Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteers", BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, Vol. 46, No. 2, August 1998, pp 111-116

EXAMINER

DATE CONSIDERED

4/11/04

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.